Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Development of strategies for the use of anti-growth factor treatments

Jones, Helen E., Gee, Julia Margaret Wendy, Taylor, Kathryn Mary, Barrow, Denise, Williams, Hywel David, Rubini, M. and Nicholson, Robert Ian 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer 12 (S1) , S173-S182. 10.1677/erc.1.01004

Full text not available from this repository.

Abstract

Aberrant signalling through the epidermal growth factor receptor (EGFR) is associated with increased cancer cell proliferation, reduced apoptosis, invasion and angiogenesis. Over-expression of the EGFR is seen in a variety of tumours and is a rational target for antitumour strategies. Among the classes of agent targeting the EGFR are small-molecule inhibitors, which include gefitinib (IRESSA™), which acts by preventing EGFR phosphorylation and downstream signal transduction. De novo and acquired resistance, however, have been reported to gefitinib and here we describe evidence which indicates that the type II receptor tyrosine kinases (RTKs) insulin-like growth factor-I receptor (IGF-IR) and/or insulin receptor (InsR) play important roles in the mediation of responses to gefitinib in the de novo- and acquired-resistance phenotypes in several cancer types. Moreover, combination strategies that additionally target the IGF-IR/InsR can enhance the antitumour effects of gefitinib.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Pharmacy
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Additional Information: This paper was presented at the 1st Tenovus/AstraZeneca Workshop, Cardiff (2005)
Publisher: Society for Endocrinology
ISSN: 1351-0088
Last Modified: 10 Oct 2017 13:38
URI: http://orca.cf.ac.uk/id/eprint/17201

Citation Data

Cited 39 times in Google Scholar. View in Google Scholar

Cited 33 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item